John Carroll

Prothena Corporation PLC (NASDAQ: PRTA) plummeted 60 percent Monday morning after a disappointing update relating to the company's treatment for AL amyloidosis. What Happened Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan...

JPMorgan Chase & Co. (NYSE: JPM) is taking heat from investors, reporters and biotech enthusiasts this week after the company decided to restrict access to its small breakout sessions following presentations at its upcoming 36th Annual Healthcare Conference in San Francisco Jan. 8-11. “...

Axovant Sciences Ltd (NYSE: AXON) nearly doubled during its first few hours of trading Thursday, stirring comments about a biotech bubble. The company acquired its single product, a prospective treatment for Alzheimer's disease, for $5 million from GlaxoSmithKline plc (ADR) (NYSE: GSK) in December...